The original disclosure in Japanese was released on October 25, 2022 at 15:00 (GMT +8)
Note: This document has been translated from the Japanese original for reference purposes only. In the event ofany discrepancy between this translated document and the Japanese original, the original shall prevail.

October 25, 2022
CompanyHeadquarters
Representative
Contact
Telephone
WebsiteTakara Bio Inc. (Securities code: 4974;Prime Market)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, in chargeof PR & IR Department(+81)77-565-6970
https://www.takara-bio.co.jp/

Notice Concerning Revisions to the First Half Financial Results Forecasts

Takara Bio Inc. hereby announces that in the light of the most recent operating trends, to revise the first half of thefinancial results forecasts for the fiscal year ending March 31, 2023 (April 1, 2022 – March 31, 2023), disclosed
on May 12, 2022, as described below.

1. Revisions to financial results forecasts
Revisions to consolidated financial results forecasts for the first half of the current fiscal year (April 1, 2022
through September 30, 2022)
Consolidated
net sales

Consolidated
operatingprofitConsolidated
ordinary
profit

Net income
attributable toowners of the parent

Net income
per share

Million yen

Million yen

Million yen

Million yen

Yen

Previously announced
forecasts (A)27,744

8,641

8,726

6,354

52.77

Revised forecasts (B)32,50010,80010,900

8,500

70.59

Change (B-A)

4,755

2,158

2,173

2,145-

Change (%)

17.1

25.0

24.9

33.8-

31,551

14,105

14,241

10,00983.12(Reference)
Actualconsolidated results
for the first half of theprevious fiscal year
(Fiscal year endedMarch 31, 2022)

The original disclosure in Japanese was released on October 25, 2022 at 15:00 (GMT +8)
2. Reason for revision
Due to the impact of the new coronavirus 7th wave, sales of related testing products are expected to exceed thepreviously announced forecasts. As other businesses are generally expected to perform in line with expectations,net sales, operating profit, ordinary profit, and net income attributable to owners of the parent are expected toexceed the previously announced forecasts. Therefore, the forecasts of consolidated financial results for the firsthalf of the current fiscal year have been revised.
After further scrutiny, we plan to release our full-year consolidated results forecasts at the time of theannouncement of our financial results for the first half on November 10, 2022.

Forward-Looking Statements
Statements contained in these materials with respect to the Company’s current plans, forecasts, strategies and beliefs that are
not historical facts are forward-looking statements about the further performance of the Company and its consolidated
subsidiaries. These statements are based on management’s assumptions and beliefs in light of information currently available
to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks anduncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence
actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as
exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and productstrategies, declines in selling power of the Company’s existing and new products, disruptions to production, violations of ourintellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.